Paper Details

  1. Home
  2. Paper Details

Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study.

Author: El-MarakbyMai G, SabriNagwa A, SolaymanMohamed H

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study analyzed the reported adverse drug reactions (ADRs) with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) using data from VigiBase.
Paper Details　
Original Abstract of the Article :
Hepatitis C virus (HCV) is the primary contributor to chronic hepatic diseases. A rapid change in the situation took place with the advent of oral direct-acting antivirals (DAAs). However, a comprehensive review of the adverse event (AE) profile of the DAAs is lacking. This cross-sectional study aim...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400676/

データ提供：米国国立医学図書館（NLM）

A Comprehensive Look at the Safety Profile of Direct-Acting Antivirals for Hepatitis C

This study delves into the [safety and efficacy of direct-acting antivirals (DAAs)] for treating Hepatitis C virus (HCV) infection, a major contributor to chronic liver disease. This research conducted a [pharmacovigilance study] to analyze reported adverse drug reactions (ADRs) associated with DAA treatment using data from VigiBase, the WHO Individual Case Safety Report (ICSR) database.

Evaluating the Safety and Efficacy of Direct-Acting Antivirals

This study provides valuable insights into the safety profile of DAAs, confirming their effectiveness in treating HCV infection. The analysis identified potential ADRs, emphasizing the need for ongoing monitoring and vigilant management to ensure patient safety. This research offers a comprehensive overview of the potential risks and benefits associated with DAA treatment.

Navigating the Treatment Landscape for Hepatitis C

This research underscores the importance of careful monitoring and management of patients undergoing DAA treatment for HCV infection. While DAAs have revolutionized HCV treatment, it's important to be aware of potential ADRs and work collaboratively with healthcare providers to ensure a safe and effective treatment experience. Remember, knowledge is power, especially when it comes to managing chronic conditions.

Dr.Camel's Conclusion

This study offers a comprehensive overview of the safety profile of direct-acting antivirals for treating Hepatitis C, highlighting the importance of vigilant monitoring and management to ensure patient safety. The findings underscore the effectiveness of DAAs while acknowledging the need for a nuanced approach to address potential adverse drug reactions.

Date :
  1. Date Completed 2023-08-04
  2. Date Revised 2023-08-07
Further Info :

Pubmed ID

37227588

DOI: Digital Object Identifier

PMC10400676

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.